Literature DB >> 8136821

Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients.

M Lopez Dupla1, M Khamashta, V Pintado Garcia, P Lavilla Uriol, E Valencia Ortega, A Gil Aguado.   

Abstract

The association of systemic lupus erythematosus (SLE) and malignancy has been reported previously and suggests an increased risk of cancer in this disease. Lymphomas are the most frequent neoplasias reported in these patients and carcinoma of the cervix and breast are also seen. Several factors probably play a role in the aetiology of malignancies associated with SLE including intrinsic disturbances of immunity and concomitant immunosuppressive therapy. We report five solid tumors (one breast carcinoma, one squamous cell carcinoma of the anus, one adenocarcinoma of the rectum, one carcinoma of the cervix and one carcinoma of the gallbladder) among 96 patients with SLE. The most striking finding in this study was the absence of haematological malignancies. The incidence of malignancy in the series, the age of diagnosis of SLE and neoplasia and the time delay between SLE and malignancy diagnosis was similar to other series. We did not find any clinical or immunological feature that predicted the development of neoplasia. In conclusion, patients with SLE may have the same malignancies as the general population after adjustment for age and sex. There are no predictive indicators for malignancy and immunosuppressive therapy may be a contributing factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136821     DOI: 10.1177/096120339300200608

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  ALK-negative T-cell anaplastic large cell lymphoma associated with systemic lupus erythematosus.

Authors:  Nada Suvajdzic; Roksanda Stojanovic-Milenkovic; Zoran Tomasevic; Vesna Cemerikic-Martinovic; Biljana Mihaljevic; Henry D E Atkinson
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  IgG deposits can be detected in cell nuclei of patients with both lupus erythematosus and malignancy.

Authors:  Ingrid Böhm
Journal:  Clin Rheumatol       Date:  2007-03-16       Impact factor: 2.980

3.  Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population.

Authors:  Waseem Khaliq; Rehan Qayyum; Jeffrey Clough; Dhananjay Vaidya; Antonio C Wolff; Diane M Becker
Journal:  Breast Cancer Res Treat       Date:  2015-05-10       Impact factor: 4.872

4.  Incidence of cancer among female patients with systemic lupus erythematosus in Korea.

Authors:  Kwi Young Kang; Hyun Ok Kim; Ho Sung Yoon; Jeniffer Lee; Won Chul Lee; Hyek-Jae Ko; Ji Hyeon Ju; Chul-Soo Cho; Ho-Youn Kim; Sung-Hwan Park
Journal:  Clin Rheumatol       Date:  2009-12-30       Impact factor: 3.650

5.  Treatment of colon cancer in a patient with systemic lupus erythematosus: a case report.

Authors:  Junfeng Shi; Jianquan Fei; Qingqing Yi; Lijuan Shen; Boshun Wan; Yueyu Chen; Qing Chang
Journal:  BMC Cancer       Date:  2018-10-10       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.